Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Summa Health

Neither a doctor nor a teaching hospital

Research payments

$550,716

287 payments

Through program year 2025, Summa Health is reported as receiving $550,716 in research payments, across 287 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $247,164 46
2024 Research $86,456 41
2023 Research $69,061 62
2022 Research $50,698 42
2021 Research $24,765 47
2020 Research $39,479 28
2019 Research $33,094 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $86,551 44 payments
  2. Cleerly, Inc. $82,495 12 payments
  3. Merck Sharp & Dohme Corporation $66,420 1 payment
  4. Novocure Inc. $59,721 16 payments
  5. GlaxoSmithKline, LLC. $57,728 14 payments
  6. Inari Medical, Inc. $51,230 65 payments
  7. Medtronic, Inc. $34,273 42 payments
  8. La Jolla Pharmaceutical Company $21,758 4 payments
  9. CSL Behring $19,354 35 payments
  10. Atricure, Inc. $17,188 26 payments
Studies the money was for Research payments · program years 2019–2025
  1. Transform $82,495 12 payments
  2. A Phase 4 Study Using A Testnegative Design to Evaluate the Effectiveness of A 20Valent Pneumococcal Conjugate Vaccine Against Vaccinetype Radiologicallyconfirmed Communityacquired Pneumonia in Adults 65 Years of Age $76,801 43 payments
  3. A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB N2 Non-small Cell $66,420 1 payment
  4. EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. $59,721 16 payments
  5. A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab M $35,327 4 payments
  6. Psr-Cvg $34,273 42 payments
  7. The Peerless Study $26,146 38 payments
  8. A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $22,401 10 payments
  9. A Single-Arm, Open-Label, Prospective, Observational Study to Assess the Safety of Sulbactam-Durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-Calcoaceticus Complex Infection $21,758 4 payments
  10. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $19,354 35 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record